Goldman Sachs and UBS have emerged as the leading mergers and acquisitions (M&A) financial advisers in South America for 2024, in terms of deal value and volume, respectively, according to the latest league table from GlobalData, a data and analytics firm.

UBS analyst Brennan Hawken raised the firm’s price target on Goldman Sachs (GS) to $640 from $610 and keeps a Neutral rating on the shares. The

UBS analyst Thomas Wadewitz revised the price target on JetBlue Airways (NASDAQ:JBLU) shares, reducing it to $5.00 from the previous target of $5.50. Despite the adjustment, the firm continues to recommend a Sell rating for the airline's stock.

The Goldman Sachs Group (NYSE:GS – Free Report) had its target price increased by UBS Group from $610.00 to $640.00 in a report issued on Tuesday morning,Benzinga reports.UBS Group currently has ...

UBS Chief Executive Sergio Ermotti on Tuesday said it was currently premature for the Swiss bank to consider acquisitions as it continues to focus on the integration of Credit Suisse, which it bought in 2023.

India and the U.S. are plugging a hole in the market for steel-making coal caused by declining demand in China which has in turn opened opportunities for investors.

Click here for access. * Consistent in their evaluation, an analyst from UBS keeps a Neutral rating on Goldman Sachs Gr with a target price of $640. * Consistent in their evaluation, an analyst ...

Goldman Sachs Group Inc (GS) stock saw a decline, ending the day at $636.9 which represents a decrease of $-2.60 or -0.41% from the prior close of $639.5. The stock opened at $630 and touched a low of $628.

Interactive Brokers Group (NASDAQ:IBKR – Get Free Report) had its target price boosted by stock analysts at UBS Group from $225.00 to $265.00 in a note issued to investors on Monday,Benzinga reports.

Indian Finance Minister Nirmala Sitharaman will present the national budget on Feb. 1, in what would be the coalition government's first full-year budget after assuming power in June. The budget comes against the backdrop of a growth slowdown in the world's fifth-largest economy,

It’s shaping up as a big year for late-stage Australian-listed drug developers, with analysts tipping potentially hefty share price rises for companies including Telix Pharmaceuticals, Clarity Pharmaceuticals and earlier-stage PYC Therapeutics.

In a report released today, James Schneider from Goldman Sachs maintained a Buy rating on International Business Machines (IBM – Research